The company is aiming for at least one outlicensing deal in the next year and Saldanha also feels pharma giant will grow at a 15-20 percent CAGR over the next five years.
first published: Dec 19, 2016 06:16 pm
A collection of the most-viewed Moneycontrol videos.
You are already a Moneycontrol Pro user.

